July 2026 in “Expert Review of Clinical Immunology” This review highlights that alopecia areata is characterized by three immune endotypes, and while JAK inhibitors offer temporary control, upcoming multi-omics diagnostics and immune reprogramming strategies may achieve longer-lasting remission, according to this analysis.
2 citations
,
March 2020 in “International Journal of Molecular Sciences” This article reviews advanced strategies for enhancing drug delivery to cutaneous stem cells to improve treatment for skin conditions and reports no new experimental findings.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
November 2025 in “Journal of Medicinal Chemistry” This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.
February 2024 in “Current Bioactive Compounds” This study explored a novel finasteride-loaded nanoparticle gel for treating alopecia areata, finding that it significantly increased hair follicle number and size without causing skin irritation, presenting an effective alternative to traditional minoxidil treatments.